IONCLAD ANTIMICROBIALS
Pre-clinical- Indications
- Healthcare-associated infections, Device-related infections
Company intelligence / Profile preview
Iasis has developed a novel antimicrobial Foley catheter with integrated Ionclad technology, which is wholly antimicrobial throughout its structure. The company has received significant grant funding for manufacturing and validation studies, including $1.25 million from the Congressionally Directed Medical Research Program for spinal cord injury applications. Additional grants have been awarded by NIH and CDC. No commercial sales yet; expected to begin commercialization activities in 2025.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Iasis Molecular Sciences.